Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: Methodology for the EXCLAIM study
| 详细信息 | 推荐本文 | |
- 作者：Russell D. Hull ; Sebastian M. Schellong ; Victor F. Tapson ; Manuel Monreal ; Meyer-Michel Samama ; Alexander G. G. Turpie ; Peter Wildgoose and Roger D. Yusen
- 关键词：Medical patients ; Low ; molecular ; weight heparin ; Prophylaxis ; Venous thromboembolism
- 刊名：Journal of Thrombosis and Thrombolysis
- 出版时间：August 2006
- 出版年：2006
- 期刊代码：91_09295305
- 类别：bio
- 卷：22
- 期：1
- 页码：31-38
- 数据来源：sp
摘要
Background: Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical patients) study is designed to compare the efficacy and safety of extended-duration thromboprophylaxis using enoxaparin with the standard regimen of enoxaparin in acutely ill medical patients with recent reduced mobility. Methods: All enrolled acutely ill medical patients receive enoxaparin 40 mg subcutaneously once daily for 10 卤 4 days. Eligible patients are then randomized in a blinded manner to receive either extended-duration thromboprophylaxis with enoxaparin 40 mg subcutaneously once daily or placebo subcutaneously once daily for an additional 28 卤 4 days. The primary efficacy endpoint is the incidence of VTE during the 28 卤 4 days after randomization. This study utilizes a standardized bilateral compression ultrasonography examination protocol that consists of an intensive interrogation of the deep veins of the lower extremities for proximal deep-vein thrombosis. The secondary efficacy endpoints are the rate of symptomatic VTE during the 3 months after randomization and mortality at 3 and 6 months after enrollment. The primary safety endpoint is the incidence of major hemorrhagic complications during the 28 卤 4 days after randomization.